Matches in Wikidata for { <http://www.wikidata.org/entity/Q66081956> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- Q66081956 description "clinical trial" @default.
- Q66081956 description "ensayu clínicu" @default.
- Q66081956 description "klinisch onderzoek" @default.
- Q66081956 description "клінічне випробування" @default.
- Q66081956 name "A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC)" @default.
- Q66081956 name "A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2" @default.
- Q66081956 type Item @default.
- Q66081956 label "A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC)" @default.
- Q66081956 label "A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2" @default.
- Q66081956 prefLabel "A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC)" @default.
- Q66081956 prefLabel "A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2" @default.
- Q66081956 P1132 Q66081956-AC972741-D941-496A-A728-548190DF0415 @default.
- Q66081956 P1476 Q66081956-0174C563-C6F0-42FD-A37C-2EBBB3B791F3 @default.
- Q66081956 P17 Q66081956-0200F76E-1BBC-45AC-8324-4287482103F7 @default.
- Q66081956 P17 Q66081956-173B21A5-67E2-4861-A5A8-B883E1849F74 @default.
- Q66081956 P17 Q66081956-3F44F101-FCED-4653-8C8E-B2EB180D99B2 @default.
- Q66081956 P17 Q66081956-5711CD0C-AD44-4308-8A6C-9B8DB313F393 @default.
- Q66081956 P17 Q66081956-8FC43501-66E2-4A44-9478-96C78A8768FC @default.
- Q66081956 P17 Q66081956-90BBF8B5-7998-4196-9649-F7CAA25C2F80 @default.
- Q66081956 P17 Q66081956-96025F17-CE2F-4B39-907D-98784649DE04 @default.
- Q66081956 P17 Q66081956-C1437C55-AB4C-41A3-A9FE-0A18CF4F884D @default.
- Q66081956 P1813 Q66081956-C4DD39CD-66B1-48D4-8D2A-A14113302D51 @default.
- Q66081956 P2899 Q66081956-0A1693A6-277B-4E28-B049-96C4C51AC881 @default.
- Q66081956 P3098 Q66081956-761CB352-3222-4626-A4A2-C552AF92272B @default.
- Q66081956 P31 Q66081956-61C66AD7-1EF6-4F2E-912D-3B91E000769E @default.
- Q66081956 P580 Q66081956-054E7CBC-08B3-4A11-9439-9D7462C56161 @default.
- Q66081956 P582 Q66081956-BD8A3E7A-DE13-47CC-97F7-625BB7CC9853 @default.
- Q66081956 P6099 Q66081956-A23437A3-F03C-4B4F-A23C-261267D638E5 @default.
- Q66081956 P6153 Q66081956-087E2125-A4AA-4740-BFB9-04E20C86B4FF @default.
- Q66081956 P6153 Q66081956-1008FAEB-9224-4369-930A-9D7B771EB8CB @default.
- Q66081956 P6153 Q66081956-22AFD8E5-1364-4F0E-AD62-5E3E53ADD103 @default.
- Q66081956 P6153 Q66081956-3D5996EE-1074-4D73-B74F-3FDF80DB29B7 @default.
- Q66081956 P6153 Q66081956-3D9C91BA-5824-4C08-B2EB-AD33C9A0846B @default.
- Q66081956 P6153 Q66081956-56A26AFC-2B2E-4989-9071-5445F51C1555 @default.
- Q66081956 P6153 Q66081956-7AFC9970-BDFA-412A-8811-6A38B8E4D46F @default.
- Q66081956 P6153 Q66081956-99A0DF31-A057-4977-BFB7-0FD0FC10CF66 @default.
- Q66081956 P6153 Q66081956-BA56CA6A-C237-4F12-BF55-EF1AC6445302 @default.
- Q66081956 P6153 Q66081956-D2EC40B1-ABEF-4516-8F37-BC41CCD71E28 @default.
- Q66081956 P8363 Q66081956-54E13605-4426-40FC-9B45-1E046124A538 @default.
- Q66081956 P859 Q66081956-8757CAE1-14A4-498D-9021-158BBB2FC713 @default.
- Q66081956 P1132 "+202" @default.
- Q66081956 P1476 "A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy" @default.
- Q66081956 P17 Q145 @default.
- Q66081956 P17 Q16 @default.
- Q66081956 P17 Q183 @default.
- Q66081956 P17 Q29 @default.
- Q66081956 P17 Q30 @default.
- Q66081956 P17 Q38 @default.
- Q66081956 P17 Q408 @default.
- Q66081956 P17 Q865 @default.
- Q66081956 P1813 "KATE2" @default.
- Q66081956 P2899 "+18" @default.
- Q66081956 P3098 "NCT02924883" @default.
- Q66081956 P31 Q30612 @default.
- Q66081956 P580 "2016-09-26T00:00:00Z" @default.
- Q66081956 P582 "2017-12-11T00:00:00Z" @default.
- Q66081956 P6099 Q42824440 @default.
- Q66081956 P6153 Q1468161 @default.
- Q66081956 P6153 Q219563 @default.
- Q66081956 P6153 Q25188472 @default.
- Q66081956 P6153 Q30254214 @default.
- Q66081956 P6153 Q30270331 @default.
- Q66081956 P6153 Q39988 @default.
- Q66081956 P6153 Q4403855 @default.
- Q66081956 P6153 Q4803501 @default.
- Q66081956 P6153 Q624119 @default.
- Q66081956 P6153 Q7063615 @default.
- Q66081956 P8363 Q78089383 @default.
- Q66081956 P859 Q212646 @default.